Form 4: Zivo Bioscience Director Acquires Stock Options

Christopher D. Maggiore, a Director and 10% owner of Zivo Bioscience, Inc., acquired 1,075 nonstatutory stock options as part of his compensation.

Summary

• Christopher D. Maggiore, a Director and 10% owner of Zivo Bioscience, Inc. (ZIVO), acquired 1,075 nonstatutory stock options.
• The transaction occurred on October 2, 2025, and was reported on October 6, 2025.
• These options were issued pursuant to the 2024 Equity Incentive Plan for Non-Employee Directors.
• The options were granted in lieu of retainer fees totaling $10,964.38.
• Each option has an exercise price of $12.03 and became exercisable on the transaction date.
• The options will expire on October 2, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction related to director compensation, which is generally neutral in sentiment. It aligns director interests with shareholders but does not indicate significant positive or negative operational or financial news.

Positives

• The acquisition of stock options by a director aligns their interests with those of shareholders, encouraging long-term value creation.
• The use of an equity incentive plan for non-employee directors is a common and accepted practice in corporate governance.

Negatives

• The issuance of new stock options can lead to minor potential dilution for existing shareholders if exercised, though this is standard for equity compensation.

Risks

• The value of the acquired stock options is subject to the future performance and market price of Zivo Bioscience, Inc.'s common stock.
• Market volatility could impact the profitability of exercising these options.

Future Outlook

This filing does not provide forward-looking statements or guidance regarding the company's future performance, focusing solely on an insider transaction.

Industry Context

The issuance of stock options to non-employee directors as part of their compensation package is a common practice across various industries, aiming to align director incentives with shareholder value creation. This transaction is consistent with typical corporate governance and compensation strategies.

Comparison to Industry Standards

• The use of equity-based compensation, specifically nonstatutory stock options, for non-employee directors is a widely adopted practice among publicly traded companies, including those in the bioscience sector.
• The structure of granting options in lieu of cash retainer fees is a standard method to conserve cash while incentivizing long-term commitment and performance, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their board members.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor potential for dilution upon exercise of options, but improved alignment of director's interests with long-term shareholder value.
• Management: The compensation structure for non-employee directors is being executed as planned, supporting governance stability.

Key Dates

Keywords

Zivo Bioscience, ZIVO, Stock Options, Director Compensation, Form 4, Insider Transaction, Equity Incentive Plan, Rule 10b5-1